Baker Bros. Advisors Amends TScan Therapeutics Stake

Ticker: TCRX · Form: SC 13D/A · Filed: 2024-04-23T00:00:00.000Z

Sentiment: neutral

Topics: 13D-A, ownership-change, biotech

Related Tickers: TCRX

TL;DR

Baker Bros. Advisors updated their TScan Therapeutics filing on 4/23. Watch this space.

AI Summary

Baker Bros. Advisors LP, through its general partner Baker Bros. Advisors (GP) LLC and principals Felix J. Baker and Julian C. Baker, has amended its Schedule 13D filing regarding TScan Therapeutics, Inc. as of April 23, 2024. The filing indicates a change in beneficial ownership, though specific new holdings or percentage changes are not detailed in this excerpt. Alexandra A. Toohey is listed as the Chief Financial Officer of Baker Bros. Advisors LP.

Why It Matters

This amendment signals a potential shift in significant ownership for TScan Therapeutics, which could influence the company's strategic direction or market perception.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often precede significant corporate actions or shifts in investor sentiment, warranting close monitoring.

Key Players & Entities

FAQ

What specific changes in beneficial ownership are detailed in this amendment?

This excerpt does not specify the exact changes in beneficial ownership, only that an amendment was filed.

When was this amendment filed with the SEC?

The amendment was filed on April 23, 2024.

Who are the principal individuals associated with Baker Bros. Advisors LP mentioned in this filing?

Felix J. Baker and Julian C. Baker are mentioned as group members.

What is the business address of TScan Therapeutics, Inc.?

The business address is 880 Winter Street, Waltham, MA 02451.

What is the CUSIP number for TScan Therapeutics, Inc. common stock?

The CUSIP number is 89854M101.

From the Filing

0001104659-24-050607.txt : 20240423 0001104659-24-050607.hdr.sgml : 20240423 20240423162552 ACCESSION NUMBER: 0001104659-24-050607 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240423 DATE AS OF CHANGE: 20240423 GROUP MEMBERS: BAKER BROS. ADVISORS (GP) LLC GROUP MEMBERS: FELIX J. BAKER GROUP MEMBERS: JULIAN C. BAKER SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92700 FILM NUMBER: 24865144 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS. ADVISORS LP CENTRAL INDEX KEY: 0001263508 ORGANIZATION NAME: IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 860 WASHINGTON STREET STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 2123395600 MAIL ADDRESS: STREET 1: 860 WASHINGTON STREET STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: BAKER BROS ADVISORS LLC DATE OF NAME CHANGE: 20030911 SC 13D/A 1 tm2412362d1_sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* TScan Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 860 Washington Street, 3 rd Floor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) April 19, 2024 (Date of event which requires filing of this statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨ . (Continued on the following pages) (Page 1 of 10 Pages) *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP No. 89854M101 Page 2 of 10 Pages 1. NAMES OF REPORTING PERSONS Baker Bros. Advisors LP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) ¨ 3. SEC USE ONLY 4. SOURCE OF FUNDS* OO 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ¨ 6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7. SOLE VOTING POWER: 2,828,938 (1) 8. SHARED VOTING POWER: 0 9. SOLE DISPOSITIVE POWER: 2,828,938 (1) 10. SHARED DISPOSITIVE POWER: 0 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 2,828,938 (1) 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ¨ 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.1% (1)(2) 14. TYPE OF REPORTING PERSON* IA, PN (1) Includes 44,146 shares of common stock (“Common Stock

View on Read The Filing